Ethical Policy
Editorial
The Society for the Study of Addiction respects and supports the independence of the journal’s editors and exerts no authority over them.
Editors' Declarations of Interest
Brief statements on senior editors' interests which might be seen as having a potential bearing on the independence of their editorial judgements. These are shown at the foot of this page. Statements by the journal’s assistant editors are held in the editorial office.
ADDICTION is a founding signatory of the Farmington Consensus. The Consensus is a series of ethical publishing guidelines for addiction journals, which 26 journals have adopted to date. The Consensus was developed in 1997 at the inaugural meeting of the group now known as the International Society of Addiction Journal Editors (ISAJE).
International Society of Addiction Journal Editors (ISAJE) Draft Ethical Guidelines
Building on the Farmington Consensus, the ISAJE Ethical Working Group has developed detailed guidelines on ethical issues. The resulting document can be found in draft form here. It endeavours to provide guidance to authors, editors and other individuals on ethical and procedural matters that affect the integrity of scientific publishing in the addiction field. We urge readers, writers, reviewers and the entire editorial network of ADDICTION to study the guidelines, to criticise them, to improve them and to use them effectively. .
Ethics Editorials
§ Click here to read the journal's policy on real or apparent breaches of ethical publishing norms by authors. “No switching off the camera. How Addiction will respond to infringements of ethical publishing expectation” (Addiction 96, 1391-1392)
§ Babor: "Ethics Matter: to authors, editors and those we serve" (Addiction 98, 1-2).
Babor's editorial offers an introduction to the ISAJE guidelines and discusses some background issues.
ADDICTION has asked its senior editors to provide brief statements on any interests which might be seen as having a potential bearing on the independence of their editorial judgements. We have done so in the belief that such transparency is owed to our authors and readers; and is fair reciprocity for the requirement on declaration of interests which we put on authors, referees and book reviewers. Senior staff are expected to distance themselves from any editorial decision-making where potential conflict of interest might be deemed to exist.
Robert West
Robert West has received travel funds and hospitality from, and undertaken research and consultancy for pharmaceutical companies that manufacture or research products aimed at helping smokers to stop. These products include nicotine replacement therapies and Zyban (bupropion). This has led to payments to him personally and to his institution. He undertakes lectures and training in smoking cessation methods which have led to payments to him personally and to his institution. He has received research grants from medical charities and government departments.
Steve Allsop
Paul
Paul
Thomas F. Babor
Thomas Babor has over the past five years conducted research projects whose funding sources have derived from federal, state or non-profit organizations, and from JBS International, Inc., a sub-contractor to the federal Center for Substance Abuse Treatment. He has received travel expenses and subsistence from the Society for the Study of Addiction, World Health Organization, US National Institutes of Health (NIAAA), and other professional organizations. Dr. Babor receives salary support not covered by grants from a PHS Endowed Chair in Community Medicine and Public Health. PHS (Physicians Health Service) is a for-profit Health Maintenance Organization that donated funding for five endowed chairs to the University of Connecticut School of Medicine. He has received no direct or indirect support from industry sources such as pharmaceutical, alcohol and tobacco companies and holds no personal stock.
Virginia Berridge is a HEFCE funded staff member of the London School of Hygiene and Tropical Medicine. She holds or has held grants from the Wellcome Trust, the Economic and Social Research Council, the Joseph Rowntree Foundation, the Alcohol Education and Research Council, the Medical Research Council and NICE, the National Institute for Health and Clinical Excellence. These are charities or government funded bodies. She has no other sources of research funding and no conflicts of interest.
Raul Caetano
For the past 25 years Raul Caetano's research has been primarily funded by the U.S. National Institutes of Health (NIAAA) and also by the U.S. Centers for Disease Control. He has received consultant fees and travel support from state offices, professional organizations, universities and other academic institutes in the
Tim Coleman
Shane Darke
Shane Darke is employed solely by the National Drug and Alcohol Research Centre, a Research Centre of the
Frances Del Boca
For the past five years, Frances Del Boca has received financial support from research grants funded by the U.S. National Institutes of Health (National Institute on Alcohol Abuse and Alcoholism). She also receives book and chapter royalties, as well as reviewing stipends, from publishing companies. To the best of her knowledge, she has no professional affiliations, society memberships, or personal stock that create conflicts of interest with her editorial responsibilities for Addiction.
GE has for many years received fees for medico-legal consultancy. He received a fee for preparing a briefing document for the British Crown Prosecution Service and has advised the Metropolitan Police. Travel expenses have been paid by WHO (
Gabriele Fischer has been the Director of the Addiction Clinic of the Medical University Vienna since 1994. Over the past years she has been involved in many national and international activities in the addiction field. She has received travel funds and undertaken research and consultancy for pharmaceutical companies (Roche, Lannacher, Aesca, Shering Plough, Mundipharma, Nepp, Astra Zenica, Wyeth), for example in the field of Opioid maintenance therapy, and Hep C treatment in opioid maintained patients. Her clinic is specialized in the treatment of opioid dependent pregnant women. Currently, Gabriele Fischer is principal investigator of an ongoing NIDA funded multicenter clinic trial on the comparison of buprenorphine and methadone maintencane therapy in opioid dependent pregnant women (RO1 DA018417). She has been involved in several EU-grants as PI. In addition she acts as a consultant for WHO, UNO and the European parliament as well as training partner for the UNODC project “International Network of Drug Treatment and
Gerhard Gmel
Over the past five years, Gerhard Gmel has received grants from various governmental and quasi-governmental sources, the Swiss National Science Foundation and the Swiss Foundation for Alcohol Research, and the World Health Organization. He is currently employed at the Swiss Institute for the Prevention of Alcohol and Drug Problems, a NGO that receives donations from the Swiss general population. He has received fees from his institute, WHO, and the Swiss government for attending international meetings. He has received no support from industry sources such as pharmaceutical, alcohol and tobacco companies and holds no personal stock.
Wayne Hall (editorial advisor)
In the past five years Wayne Hall has not received fees or funding of any kind from alcohol, pharmaceutical or tobacco companies. His research funding has been from the following public funding sources: the Australia Research Council, the Australian Alcohol Education and Research Fund, the National Health and Medical Research Council of Australia, and the National Prescribing Service (a government-funded service that advises prescribers on evidence fro clinical prescribing).
Keith Humphreys
Martin Y. Iguchi
Martin Y. Iguchi has conducted research over the past 20+ years with funding from a variety of US Government sources (National Institutes of Health (NIDA, NIMH); Substance Abuse and Mental Health Services Administration (CSAT; CSAP; CMHS); Alcohol, Drug Abuse, and Mental Health Administration (NIDA); Health Resources and Services Administration; New Jersey State Department of Health; City of Newark, New Jersey), and non-profit organizations (Robert Wood Johnson Foundation; Ford Foundation; Russell-Sage Foundation; Foundation of the University of Medicine and Dentistry of New Jersey). He has also been a paid consultant to non-profit agencies working as subcontractors to the
Jerome H. Jaffe
Over the past five years JHJ has received travel expenses, consulting fees, or hospitality from various industry sources. Among them are several companies whose interests include the development of medications or technologies that have or may have a bearing on the treatment of pain, the misuse of drugs, or the management of treatment systems. The medications include methadone, LAAM, buprenorphine, oxycodone, Zolpidem, and a peripheral opioid antagonist, (ADL-2698). The technologies include methods to detect drugs in oral fluids, to reduce tobacco specific nitrosamines in tobacco, and to develop tobacco products with reduced levels of tobacco specific nitrosamines and other toxins. He has also been paid fees for providing medical-legal advice on a matter relating to the appropriate medical treatment of individuals with drug problems. Honoraria and/or travel expenses have been paid by universities in the US and Europe, US government agencies or their contractors, other public and private agencies in the US concerned with the delivery of drug abuse treatment services, and professional societies in the US, Europe, and the UK. Royalty fees or honoraria have been paid by a number of academic publishers. Institutional support has been provided by the University of Maryland School of Medicine. JHJ serves pro-bono as advisor on a number of research grants, funded by public and private agencies, that deal with diverse public health and drug abuse treatment issues, drug development and safety, and the basic science of drug abuse. He does not, himself, receive any research grant support.
Lynn Kozlowski
Lynn Kozlowski's statement refers to the past five years. He has conducted research projects whose funding derived from the
Harry Lando has received travel funds and has consulted with pharmaceutical companies that manufacture products intended to help smokers to quit. These products include nicotine replacement, Zyban (bupropion), and Chantix (Varenicline). As of May 2006 he no longer accepts compensation or consulting from the pharmaceutical industry. His research is primarily funded by the U.S. National Institutes of Health. Additional funding sources have included the Department of Defense, the Robert Wood Johnson Foundation and ClearWay
Paul Lemmens
Pia Makela
John Marsden
John Marsden has over the past five years held research grants from the English Department of Health, Medical Research Council, European Commission and the European Monitoring Centre on Drugs and Drug Addiction to support the development and implementation of randomised controlled trials of behavioural and pharmacological interventions, studies of prisoner drug-related behaviour and mortality, reviews of the research field in the addictions, and survey of synthetic cathinone use, respectively. He has also received institutional support to conduct a genetic association study of methadone and buprenorphine maintenance treatment from Reckitt-Benkiser (the manufacturers of buprenorphine). John has received technical consulting income from Quest Consulting (a UK management consultancy operating in the health and social care field), the Home Office and from the National Treatment Agency for Substance Misuse. He has received fees for legal reports, journalism, and for presenting and other professional contributions to scientific productions on UK television and radio. Dr Marsden has also received reimbursement for travel, accommodation and subsistence costs to attend scientific and other professional meetings from the Society for the Study of Addiction and Reckitt-Benkiser (the latter via an untied educational grant to the Department of Clinical and Experimental Pharmacology, University of Adelaide).
Barbara McCrady
Barbara McCrady has over the past five years conducted research and program evaluation projects funded by the US National Institutes of Health (NIAAA and NIDA), the State of
Andy McEwen
Andy McEwen receives a personal income from Cancer Research UK via University College London. He has received travel funding, honorariums and consultancy payments from manufacturers of smoking cessation products (Pfizer Ltd, Novartis and GSK Consumer Healthcare Ltd). He also receives payment for providing training to smoking cessation specialists and receives royalties from books on smoking cessation.
Michael John Morgan
From 1991-2005 he has held University posts funded by the
Maxine Stitzer
Maxine Stitzer has over the past five years conducted research projects whose funding sources have derived solely from federal agencies (NIDA, NCI). She has received personal fees and travel expenses from US National Institutes of Health (NIDA), Veterans Administration,
Michael Ussher
Michael Ussher has no affiliations which he believes constitute a conflict of interest. Michael is employed by
© 2006 Blackwell Publishing Ltd.